Skip to content
10-Q

Quarterly Report

CHAMPIONS ONCOLOGY, INC. CSBR

0001628280-26-017345

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Mar 11, 2026 13.89M sh
Shares Diluted Q3 2026 · Jan 31, 2026 13.89M sh
Shares Diluted Q3 2026 · Jan 31, 2026 13.81M sh
Shares Diluted Q3 2026 · Jan 31, 2025 14.36M sh
Shares Diluted Q3 2026 · Jan 31, 2025 14.13M sh
Capex Q3 2026 · Jan 31, 2026 $325K
Capex Q3 2026 · Jan 31, 2025 $136K
Operating Cash Flow Q3 2026 · Jan 31, 2026 −$2.47M
Operating Cash Flow Q3 2026 · Jan 31, 2025 $518K
Cash And Equivalents Q3 2026 · Jan 31, 2026 $7.13M
Cash And Equivalents Q3 2026 · Apr 30, 2025 $9.79M
Stockholders Equity Q3 2026 · Jan 31, 2026 $4.28M
Stockholders Equity Q3 2026 · Apr 30, 2025 $3.77M
Current Liabilities Q3 2026 · Jan 31, 2026 $20.68M
Current Liabilities Q3 2026 · Apr 30, 2025 $23.85M
Total Liabilities Q3 2026 · Jan 31, 2026 $24.07M
Total Liabilities Q3 2026 · Apr 30, 2025 $28.57M
Current Assets Q3 2026 · Jan 31, 2026 $20.19M
Current Assets Q3 2026 · Apr 30, 2025 $22.36M
Total Assets Q3 2026 · Jan 31, 2026 $28.45M
Total Assets Q3 2026 · Apr 30, 2025 $32.34M
Eps Diluted Q3 2026 · Jan 31, 2026 −$0.02
Eps Diluted Q3 2026 · Jan 31, 2026 −$0.04
Eps Diluted Q3 2026 · Jan 31, 2025 $0.31
Eps Diluted Q3 2026 · Jan 31, 2025 $0.46
Eps Basic Q3 2026 · Jan 31, 2026 −$0.02
Eps Basic Q3 2026 · Jan 31, 2026 −$0.04
Eps Basic Q3 2026 · Jan 31, 2025 $0.33
Eps Basic Q3 2026 · Jan 31, 2025 $0.48
Sga Expense Q3 2026 · Jan 31, 2026 $2.98M
Sga Expense Q3 2026 · Jan 31, 2026 $8.52M
Sga Expense Q3 2026 · Jan 31, 2025 $2.4M
Sga Expense Q3 2026 · Jan 31, 2025 $6.81M
Rd Expense Q3 2026 · Jan 31, 2026 $2.27M
Rd Expense Q3 2026 · Jan 31, 2026 $6.97M
Rd Expense Q3 2026 · Jan 31, 2025 $1.72M
Rd Expense Q3 2026 · Jan 31, 2025 $4.86M
Net Income Q3 2026 · Jan 31, 2026 −$279K
Net Income Q3 2026 · Jan 31, 2026 −$508K
Net Income Q3 2026 · Jan 31, 2025 $4.5M
Net Income Q3 2026 · Jan 31, 2025 $6.54M
Operating Income Q3 2026 · Jan 31, 2026 −$276K
Operating Income Q3 2026 · Jan 31, 2026 −$618K
Operating Income Q3 2026 · Jan 31, 2025 $4.5M
Operating Income Q3 2026 · Jan 31, 2025 $6.56M
Cost Of Revenue Q3 2026 · Jan 31, 2026 $8.83M
Cost Of Revenue Q3 2026 · Jan 31, 2026 $24.09M
Cost Of Revenue Q3 2026 · Jan 31, 2025 $6.62M
Cost Of Revenue Q3 2026 · Jan 31, 2025 $21.12M
Revenue Q3 2026 · Jan 31, 2026 $16.56M
Revenue Q3 2026 · Jan 31, 2026 $45.59M
Revenue Q3 2026 · Jan 31, 2025 $17.04M
Revenue Q3 2026 · Jan 31, 2025 $44.59M